Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Calumet Announces $65 Million At-the-Market Equity Offering Program

In This Article:

INDIANAPOLIS, Jan. 14, 2025 /PRNewswire/ -- Calumet, Inc. (NASDAQ: CLMT) (the "Company" or "Calumet") today announced that the Company has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the "SEC") establishing an at-the-market equity offering program (the "ATM Program") under which it may issue and sell, from time to time, shares of its common stock having an aggregate gross sales price of up to $65 million (the "Offered Shares"). Calumet intends to use the net proceeds from the ATM Program for general corporate purposes, which may include, among other things, repayment of indebtedness, working capital and capital expenditures.

Pursuant to the ATM Program, Calumet may issue and sell, at its discretion, the Offered Shares to the public from time to time, at the market prices prevailing at the time of sale, at prices related to the prevailing market prices or at negotiated prices, in each case on or through the Nasdaq Global Select Market or any other national securities exchange where the Offered Shares may be traded, and, as a result, prices at which the Offered Shares are sold may vary among purchasers and during the period of any distribution.

Pursuant to the terms of the equity distribution agreement (the "Equity Distribution Agreement"), dated January 14, 2025, between Calumet and BMO Capital Markets Corp. (the "Sales Agent"), sales of the Offered Shares, if any, under the ATM Program will be made in sales deemed to be "at the market offerings" as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. The Sales Agent may also sell the Offered Shares by any other method agreed in writing between Calumet and the Sales Agent and permitted by applicable law, including, without limitation, as block transactions. Subject to the terms and conditions of the Equity Distribution Agreement, the Sales Agent will use its commercially reasonable efforts, consistent with normal trading and sales practices and in accordance with applicable law and regulations, to sell on Calumet's behalf all of the Offered Shares designated by Calumet pursuant to a placement notice. There is no minimum amount of funds that must be raised under this offering.

The offering is being made pursuant to a prospectus supplement dated January 14, 2025 to the Company's base prospectus included in its registration statement on Form S-3 filed with the SEC on January 14, 2025. Before making an investment in the Offered Shares, potential investors should read the prospectus supplement and the accompanying base prospectus for more information about Calumet and the ATM Program. Copies of the prospectus supplement, the accompanying base prospectus and the Equity Distribution Agreement are available on the SEC's website at www.sec.gov. Potential investors can request copies of the prospectus supplement and the accompanying base prospectus from the Sales Agent by contacting: BMO Capital Markets Corp., Attn: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036 or by email at bmoprospectus@bmo.com.